Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation

Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable tumors, no standard care exists. While crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is only approved for non-small-cell lung cancer...

Full description

Saved in:
Bibliographic Details
Published in:Intern Med
Main Authors: Ogata, Misato, Hatachi, Yukimasa, Ogata, Takatsugu, Satake, Hironaga, Imai, Yukihiro, Yasui, Hisateru
Format: Artigo
Language:Inglês
Published: The Japanese Society of Internal Medicine 2018
Subjects:
Case Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6478978/
https://ncbi.nlm.nih.gov/pubmed/30449794
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.1640-18
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items